;) EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD • BioPharmCatalyst biopharmcatalyst.com Biotech catalyst calendars and ...
$AVNS agreed to be acquired by affiliates of American Industrial Partners in an all-cash deal valuing the company at biopharmcatalyst.com/news/2026/avan… ...
In this episode, John Gagliano and Chef Sheffield review the biotech landscape of 2025, discussing key trends, FDA clarity, and the impact of CRLs on investor confidence. They highlight significant ...
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028. The FDA has approved a subcutaneous version of ...
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Comprehensive Data on Public and Private Biotech Companies Now Available to Enhance Investment Decisions SAN DIEGO, Jan. 9, 2025 /PRNewswire-PRWeb/ -- BioPharmCatalyst, a trusted source for clinical ...
Bringing together over 8,000 industry leaders, emerging innovators and influential investors, the J.P. Morgan (JPM) Healthcare Conference is the most significant catalyst event for the healthcare ...
BioPharmCatalyst (BPC), a division of Scientist.com and a trusted platform for biotech investors and life science professionals, has unveiled “Aiden,” its new AI-powered chatbot. Designed to enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results